Core Insights - The nuclear technology application industry in China is experiencing rapid growth, with an expected market size nearing 900 billion RMB by the end of 2024 and projected to exceed 1 trillion RMB by 2025, maintaining an annual growth rate of over 15% [1] - Significant innovations have emerged, including the successful implementation of domestic heavy ion therapy devices and the introduction of the world's first phased array CT and ultra-large aperture spiral CT, indicating a notable advancement in China's independent innovation capabilities in high-end medical equipment and radioactive pharmaceuticals [1] - The industry is positioned to contribute to green and low-carbon transformation through efficient and clean nuclear technology applications, such as the large-scale application of electron beam wastewater treatment technology [1] Industry Development - Nuclear technology applications are recognized as a typical representation of new productive forces, directly supporting nine goals of the United Nations 2030 Sustainable Development Agenda [2] - The nuclear technology application industry is expected to double in size by around 2030, with significant improvements in development quality and the establishment of a reliable and efficient nuclear technology application infrastructure [2] - The National Atomic Energy Agency is leading the formulation of development guidelines for the nuclear technology application industry, aiming for a scale increase of 4-5 times by 2035, focusing on technology innovation, policy optimization, supply chain completeness, and global integration [3] Conference Highlights - The conference themed "Nuclear Technology Promoting Global Sustainable Development" aims to create a high-level dialogue platform for global nuclear technology applications, discussing technological innovation, industrial collaboration, and international cooperation [4] - Representatives from international organizations such as the International Atomic Energy Agency and participants from 17 countries, including the USA, UK, and France, attended the conference, highlighting the global interest in nuclear technology applications [4]

Core Insights - The Chinese nuclear technology application industry has entered a period of rapid development over the past decade, with an estimated market size approaching 900 billion RMB by the end of 2024, maintaining an annual growth rate of over 15%, and is expected to exceed 1 trillion RMB by 2025 [1] Industry Developments - Significant innovations have emerged in recent years, including the successful deployment of domestic heavy ion therapy devices, the introduction of the world's first phased array CT and ultra-large aperture standing spiral CT, and the establishment of Asia's largest radiation source R&D and production base in Jiajing [1] - Nuclear technology is becoming a crucial support for achieving the "dual carbon" goals, with applications in irradiation processing, advanced manufacturing, and wastewater treatment, leveraging its efficient and clean advantages to promote green low-carbon transformation [1] Legal Framework - The recent passage of China's first "Atomic Energy Law" on September 12, which clearly defines nuclear technology applications as a key component, is expected to inject stronger legal guarantees and development momentum for the high-quality development of the industry [1]

Core Insights - The Chinese nuclear technology application industry has made significant progress, with the industry scale reaching new heights and achieving breakthroughs in high-quality development [1] Industry Overview - The output value of China's nuclear technology application is projected to reach 890 billion yuan in 2024, accounting for 0.66% of GDP, which is a 27% increase from 2022 [1] - The compound annual growth rate from 2020 to 2024 is estimated at 15.6% [1] - The distribution of application sectors includes industrial applications (42.7%), nuclear medicine (21.7%), agricultural applications (13.9%), and foundational industries (10.3%) [1] Workforce and Infrastructure - By the end of 2024, there will be approximately 140,000 legal entities engaged in radioactive isotope/radiation device operations, employing around 960,000 people, representing growth of 34% and 17% respectively since 2022 [1] - The number of radiation devices in use is about 320,000 units, with 172,000 radioactive sources, marking increases of 17% and 4.9% respectively since 2022 [1] - There are 42 national large-scale scientific facilities related to nuclear technology, with 18 operational research reactors, including 5 capable of isotope production [1] Technological Advancements - The industry has seen rapid development in irradiation processing and nuclear medical applications, with growth rates exceeding double digits [2] - The production value of nuclear agricultural applications has surpassed 100 billion yuan, and the market penetration of various nuclear analysis and instrumentation products continues to rise [2] - Significant advancements include the approval of the world's first phased array CT and the domestic first photon counting spectral CT, among other innovations [3] International Collaboration - China has opened 12 top nuclear research facilities to the international community and established 8 IAEA collaboration centers [3] - Equipment for Thailand's micro-reactor project has been shipped, and there is a growing trend in the export of high-end nuclear medical devices and industrial irradiation equipment [3]

近年来，国内涌现出一批重大创新成果，为我国核技术产业规模加速扩大提供了助力。国产重离子治疗 装置成功落地、全球首台相控阵CT及超大孔径立位螺旋CT问世、夹江建成亚洲最大放射源研发生产基 地等，这些都标志着我国在高端医疗装备、放射性药物等关键领域的自主创新能力实现跃升。 "与此同时，核技术也成为推动我国'双碳'目标实现的重要支撑。"曹述栋说，在辐照加工、先进制造、 废水处理等方向，核技术凭借其高效、清洁的独特优势，有力助推绿色低碳转型。我国电子束处理废水 技术已实现规模化应用，为全球环境治理贡献了"中国智慧"与"中国方案"。 新华财经北京10月15日电（记者安娜）核技术正日益成为推动社会现代化进程的重要引擎。中国核能行 业协会常务副理事长曹述栋预计，2025年我国核技术应用产业规模将突破万亿元大关。 曹述栋是在10月15日由中国核能行业协会主办的2025年核技术应用产业国际大会上作出上述表述的。 记者从会上了解到，目前，全球已有150多个国家在不同层面开展核技术应用，涵盖工业、医疗、农 业、社会安全、科研、环境保护乃至考古文保等诸多领域。 "过去十年，我国核技术应用产业迈入高速发展期，初步统计，至2024年底， ...

Group 1 - The medical sector is active, with the largest medical ETF in A-shares (512170) seeing a price increase of over 1% and a trading volume of 322 million yuan, ranking first among similar ETFs [1] - The latest fund size of the medical ETF is 27.36 billion yuan, with significant gains in constituent stocks such as Meihao Medical, Kaili Medical, and Huaxi Biological, where Meihao Medical hit a 20% limit up [1] - Major weighted stocks like Mindray Medical and United Imaging also experienced gains exceeding 3% [1] Group 2 - Gilead Sciences announced a 100% prevention efficacy of its HIV-1 capsid inhibitor lenacapavir in phase 3 clinical trials [3] - Major companies like Midea and Haier are accelerating their investments in the healthcare sector, focusing on medical imaging and low-temperature storage [3] - The medical device sector is benefiting from policy support and innovation, with a focus on high-certainty performance in specific sub-sectors during the mid-year reporting period [3] Group 3 - The National Healthcare Security Administration has published an initial review list for innovative drugs, indicating a significant increase in the number of drug generic names passing initial review compared to 2024 [3] - The "anti-involution" principle in centralized procurement is established, leading to a gradual easing of policy impacts, which may improve profitability in the medical device industry [3] - The domestic leading companies in the in-vitro diagnostics field are rapidly increasing their market share, and high-value consumables are expected to see a recovery in performance and valuation due to the easing of centralized procurement policies [3]

Group 1 - The core viewpoint of the article highlights the revolutionary development of the world's first phased array CT, which enables doctors to observe lung nodules smaller than 2mm and accurately distinguish between benign and malignant nodules, thus avoiding unnecessary surgeries and excessive medical interventions [1] - The phased array CT technology represents a significant leap in CT technology, with all core components developed and fully localized by Beijing Nanwei Jing Technology Co., Ltd. [1][5] - The phased array CT's optical rotation mode disrupts the traditional mechanical rotation model, allowing for a significant increase in scanning speed and image quality [2][3] Group 2 - The phased array CT can produce ultra-high-definition medical images with a pixel resolution of 3072×3072, enhancing spatial resolution by 64 times and temporal resolution by 3 times compared to traditional spiral CT [2][3] - Nanwei Jing has developed key technologies such as photon flow detectors and distributed X-ray source arrays, overcoming the limitations of traditional CT detectors that relied on imports [3][4] - The successful development of the phased array CT marks a historic transition for China's high-end medical equipment industry from being a technology follower to a leader in the CT technology field [5]

Core Insights - The first phased array CT in the world has been established in Shanghai, with the development company confident in obtaining Class III medical device certification within the year [1] - The phased array CT technology offers ultra-high-definition imaging of lung pathology, significantly surpassing conventional CT in pixel resolution [1] - The phased array CT is fully self-developed, addressing critical issues in high-end medical imaging equipment and promoting domestic production needs [2] Company Developments - The phased array CT, developed by Nanwei Vision, will undergo approximately 400 clinical trials led by Shanghai Ruijin Hospital, with expectations for Class III certification by the end of 2025 [1] - The core components of the phased array CT, such as the photon flow detector and integrated detection chips, are crucial for domestic manufacturing and have a significant impact on the industry supply chain [2] Industry Impact - The introduction of the phased array CT is expected to create new diagnostic standards and applications in the medical field, particularly enhancing precision in orthopedic minimally invasive surgeries and managing osteoporosis [2]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...